The 2026 U.S. Addiction Policy Landscape
Telehealth is extended. Settlement money is flowing. Medicaid is uncertain. What policy actually looks like right now.
Body: Policy in 2026 is a rare mix of tailwinds and risks. On the tailwinds side: DEA and HHS extended telemedicine flexibilities for controlled substance prescribing through December 31, 2026 — and a final rule now permanently allows buprenorphine prescribing via telehealth for up to six months without an in-person visit. That’s a generational change in how OUD care can be delivered.
SAMHSA’s State Opioid Response (SOR) grants continue to fund states at ~$1.5B annually for prevention, treatment, and recovery. HHS has been receptive to Medicaid IMD exclusion waivers, which allow reimbursement for residential treatment at larger facilities — potentially unlocking capacity.
On the risk side: Proposed Medicaid work requirements and potential ACA rollbacks could reduce SUD coverage for the populations that need it most. Any shift here reshapes the economics of treatment overnight.
And then there’s the money nobody is talking about enough — the opioid settlements. Arizona alone is receiving $1.215 billion over 18 years. Nationally, settlements are approaching $50 billion. How states spend this will define the next decade of infrastructure.
Related reads: DEA extends telemedicine buprenorphine | What SAMHSA SOR grants actually do | The Arizona opioid settlement, explained.
Sources Cited
- 01.A
- 02.A
- 03.Ahttps://nationalopioidsettlement.comNational Opioid Settlement
Filed Under
SAMHSADEAOpioid SettlementFederalGovernment DataPolicy
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
The Overdose Numbers Are Falling. Cocaine Is the Exception Nobody's Toasting.
CDC data show overdose deaths falling nationally, but stimulant-only deaths are rising, and Medicaid coverage for the one treatment that works, contingency management, remains rare.
Policy & FundingSAMHSA Killed Funding for Fentanyl Test Strips. Then CDC Bragged About Falling Overdose Deaths.
SAMHSA cut federal funding for fentanyl test strips and syringes in April. Five months later, CDC's new overdose dashboard shows deaths falling 12.3% — and harm reduction groups in Kentucky, Ohio, and South Carolina are the ones absorbing the contradiction.
Policy & FundingDEA Drew a Real Line on Kratom. Whether It Holds Isn't Decided Yet.
The federal comment period on DEA's proposed 0.05% threshold for 7-hydroxymitragynine closed September 10, 2026. Here's the real state of kratom scheduling right now — and what it doesn't change.